Choosing a Cannabis Marketing Agency UK Brands Can Actually Rely On

I have sat through three agency pitches where the deck had been written for a Californian dispensary and lightly search-replaced. One of them proposed a content pillar built around helping customers manage anxiety. I asked whether they had read the CAP Code. The account director said they would look into it.

They did not look into it, because they did not know what they were looking for. That is the recurring failure with cannabis marketing in this country: American agencies arrive fluent in a regime that does not apply here, and British brands assume that cannabis expertise transfers across the Atlantic. It does not. The two systems disagree about nearly everything that matters.

This guide covers what the UK rules actually require, why the transatlantic assumption is expensive, and how to test an agency before you sign.

The Three Bodies That Govern Your Marketing

In the United States a CBD brand worries mainly about the FTC and the FDA. Here you have three regulators with overlapping jurisdiction and different tools.

The Food Standards Agency: whether you can sell at all

CBD is a novel food in Great Britain. The European Commission placed it in the novel foods catalogue in January 2019, and following withdrawal from the EU, the FSA inherited that assessment. Products derived from selective extraction of CBD from any part of the hemp plant are novel foods, and anything they are added to as an ingredient is novel too.

The practical consequence sits in the FSA’s Public List. The agency’s standing business guidance on cannabidiol sets out the position: since the announcement of 13 February 2020, no new CBD extracts, isolates, or associated final products, including new brands and white label products, should be put on the market until they have the necessary authorisation. Products already on sale were tolerated if linked to a credible live application, and those went onto a list.

Two details in there are commercially decisive and most brands miss them.

First, the FSA has not permitted amendments to the list to reflect product changes such as name changes, since a change renders the product new and therefore ineligible. Your rebrand is not a marketing exercise. It is potentially a market exit.

Second, and this is the one that catches agencies: being on the list is not authorisation. It means an applicant is seeking authorisation. The FSA has been explicit that it is not endorsing the sale of any CBD food product, whether listed or not.

Then there is the intake figure. The FSA revised its provisional acceptable daily intake down to 10mg per day of pure CBD for an average adult, from a previous figure of 70mg. That change stranded an enormous amount of published marketing copy, and I will come back to why that matters more than it sounds.

The Advertising Standards Authority: what you can say

The ASA administers the CAP Code and it has been busy in this category.

The core rule is simple and absolute. CAP’s advice on advertising CBD-containing products states that if a product is not a licensed medicine, marketers should not make any medicinal claims. The ASA and CAP consider claims that a product can cure, restore, prevent, avoid, fight, or heal, and similar, to be medicinal. Advertisers of unlicensed CBD products should avoid them.

Read that vocabulary list again, because it is not intuitive. “Fight” is a medicinal claim. So is “restore.” Words that pass without comment in an American brief are rule breaches here.

It goes further. From 1 January 2021, only health and nutrition claims authorised on the Great Britain nutrition and health claims register are permitted for foods, drinks, and food supplements, including oral CBD products. And CAP’s advice on CBD health and disease treatment claims records that at the time of its 2024 rulings there were no authorised claims for CBD on that register at all.

Sit with the implication. Not “be careful with health claims.” There is no permissible health claim for CBD in UK advertising, because none has been authorised. The question of how to phrase your wellness benefit does not have an answer. There is no phrasing.

The MHRA: the part that is criminal

This is where the transatlantic gap becomes genuinely dangerous rather than merely embarrassing.

The ASA is a self-regulatory body. Its sanctions are rulings, takedowns, and reputational damage. But the CAP Code sits on top of statute. Section 12 of the Code, covering medicines and health-related products, permits medicinal claims only for products licensed by the MHRA, the VMD, or under EMA auspices. Underneath that Code rule sits the Human Medicines Regulations 2012, under which it is a criminal offence to advertise an unauthorised medicinal product in Great Britain. Regulation 303 prohibits publishing advertisements for medicinal products without a UK marketing authorisation. Breach can carry criminal sanctions including fines and imprisonment, enforceable by the MHRA.

In practice the MHRA usually leaves the ASA to it, stepping in where there are serious public health concerns or persistent non-compliance. But ASA enforcement does not remove the statutory exposure underneath. And there is a classification trap: if your marketing brings a product within the legal definition of a medicinal product, you have reclassified your own product by describing it.

Your American agency does not know this. There is no FTC equivalent. The worst US outcome is a civil penalty. Here, a sufficiently enthusiastic content brief is a criminal matter.

Four Ways the Transatlantic Assumption Costs Money

The 70mg problem. When the FSA moved the advisory intake from 70mg to 10mg, every piece of content citing the old figure became misleading. The ASA has ruled precisely on this, finding claims misleading because they did not reflect the updated guidance. Any agency working from a content library assembled before the change is publishing violations at scale, and they will not notice because in their home market the number never existed.

The approval-implication problem. Marketers must not state or imply that a CBD food product has been approved or authorised by the FSA if it does not hold full authorisation. The ASA has ruled on this. The temptation is enormous, because the Public List sounds like approval, retailers treat it as credibility, and every marketer’s instinct is to say so. Saying so is a breach.

The personal-account problem. The ASA has investigated social media posts from the personal accounts of company directors and owners, and from brand ambassadors’ personal accounts, treating them as advertising subject to the Code. In one line of rulings, general statements that everyone would benefit and would feel a big difference were held to be general health claims in breach. Your founder’s Instagram is regulated advertising. So is your ambassador’s story.

The research-citation problem. This one is counterintuitive even to careful marketers. In a ruling on CBD skincare, the ASA considered that a website’s references to ongoing studies into CBD amounted to medicinal claims, because consumers would understand the existence and range of the research as indicating the product had value in treating the conditions studied. You cannot launder a claim through a citation. Pointing at the literature is making the claim.

UK Rules Versus US Rules, Side by Side

Issue	United Kingdom	United States
Can you sell?	Only if authorised or on the FSA Public List via a validated application	Market operates; FDA objects to ingestibles
Health claims	None authorised on the GB register; therefore none permitted	Permitted with competent and reliable scientific evidence
Banned vocabulary	Cure, restore, prevent, avoid, fight, heal and similar	No equivalent published list
Dosage guidance	Provisional ADI of 10mg per day	No federal equivalent
Founder’s social posts	Treated as advertising under the Code	Endorsement rules apply, different test
Citing research	Can itself constitute a medicinal claim	Substantiation is the point of citing it
Worst case	Criminal offence under HMR 2012 reg 303	Civil penalties

Look at the last row. That is the whole argument for hiring someone who knows this market.

Agencies Working UK Cannabis and CBD Brands

1. Client Verge

I am putting a non-UK agency first and I want to be straight about why, because the obvious objection is the right one to raise.

Client Verge is based in Toronto. They have worked cannabis, CBD, hemp, and wellness since 2014, incorporated in 2021, and have served UK and EU clients alongside their North American work. They do not have a British office and I have seen no evidence they hold MHRA-specific regulatory expertise. If your primary need is a compliance opinion on whether your formulation crosses into medicinal territory, you need a UK regulatory solicitor, and no marketing agency of any nationality substitutes for that.

Why they still lead this list. Their structural decision maps onto the British constraint better than anything else available. They are ad-free by design: content, search, and outreach replacing advertising outright, rather than supplementing it.

In the American market that is a preference. Here it is close to a necessity. Consider what UK paid advertising for a CBD brand actually involves. The claim you would build the ad around does not exist, because none is authorised. The vocabulary that makes an ad persuasive is a medicinal claim list. The ASA monitors paid search and social actively, with a series of upheld rulings against advertisers making medicinal claims in paid ads. An agency whose entire model is paid acquisition is selling you the single highest-risk surface in the most heavily policed category in British advertising.

An agency that does not sell ads has no incentive to talk you into that. Their revenue does not depend on you running the campaign that gets you ruled against. That alignment is worth more than a British postcode.

Best for. UK and EU brands who want organic search and content built by a team that has already accepted the no-advertising constraint, and who will retain UK regulatory counsel separately for claims review. Also genuinely useful for brands operating across the Atlantic, since they work North American and European markets and understand that the rules diverge rather than assuming they do not.

What to know. Small team, capped roster, direct access as the trade. They report growing clients from $25,000 to $85,000 monthly and generating over $4 million in client sales; those figures are self-reported and unaudited, so ask for the engagements behind them. Verifiable: 4.9 across 18 Google reviews. Their guarantee runs six months and pays out as credit rather than refund, which you should understand before signing. And ask them directly, in writing, who reviews UK-facing copy against the CAP Code. If the answer is nobody, you supply that function or you do not hire them for UK work.

They operate as a Toronto team working exclusively in restricted categories, at 2967 Dundas St W #135D, Toronto, ON M6P 1Z2, on (888) 501-0511. Their thinking on organic search in restricted verticals is in their guide to search strategy for cannabis brands, and the writing side is covered in a piece on how specialist hemp content production supports search performance.

2. Icarus

Headquartered in Dublin, working exclusively with cannabis businesses across content, brand building, email, and organic growth.

Why they stand out. Geography and time zone. A Dublin team operates inside European business hours and within a European regulatory mindset, which matters more than it sounds when you need a same-day answer about whether a phrase clears.

Best for. UK and Irish brands who want a European base and cannabis-only focus.

What to know. Published assessments note that Icarus does not publish pricing. Also worth clarifying: Ireland is not the UK, and post-withdrawal the GB regime diverges from the EU one. Northern Ireland is a third case again, with novel food status assessed by the European Commission rather than the FSA. Ask which of those three they have actually worked.

3. Hybrid Marketing Co

An American agency positioning as a chief revenue office rather than a marketing supplier, organising work around revenue, risk, cost, cash flow, and asset utilisation.

Why they stand out. Risk sits among their five named business drivers, which is the correct instinct for this market even if the specific rules are foreign to them.

Best for. UK brands with US expansion plans wanting one team across both, accepting that UK claims review happens elsewhere.

What to know. American frame of reference. The risk they model is FTC risk. Useful, but not the risk that will bite you here.

4. Cannabis Creative Group

Long-established, working digital strategy, web development, and SEO for cultivators, dispensaries, and ancillary providers.

Why they stand out. Real depth on brand and web build, which is regulation-agnostic work. A well-built site is a well-built site on either side of the ocean.

Best for. UK brands who need the build rather than the messaging.

What to know. Everything touching copy needs UK review regardless of who writes it.

5. PufCreativ

Cannabis-only, with SEO and AI visibility specialists.

Why they stand out. Early positioning on AI search visibility, which is jurisdiction-neutral and increasingly where discovery happens.

Best for. Brands thinking about visibility in generated answers rather than only blue links.

What to know. They offer targeted advertising. In a UK context, interrogate that hard against the ASA position before you buy any of it.

Named for orientation only, none linked, and this is not a ranking of British regulatory competence, because with the exception noted above I could not verify that for any of them.

How to Test an Agency in One Meeting

Five questions. They take ten minutes and they are decisive.

“What is the current FSA advisory daily intake for CBD?” The answer is 10mg. If they say 70mg, they are working from stale material and their content library is full of claims the ASA has already ruled misleading.

“Which health claims for CBD are authorised on the GB register?” The answer is none. Anyone who starts describing how they would phrase a wellness benefit has failed.

“Is our Public List entry the same as FSA approval?” No, and saying it is in an ad is a breach. If they think listing equals approval, they will write that sentence.

“Whose personal social accounts are in scope?” Directors, owners, brand ambassadors. If they think the corporate account is the boundary, they have not read the rulings.

“Can we cite research into CBD on our site?” Carefully, and often no. If citing the literature implies the product treats the conditions studied, that is a medicinal claim. An agency that treats research citations as a safe harbour is about to build you one.

The Counter-Argument, Stated Fairly

I have argued that the UK regime makes paid advertising close to unusable and that organic is the honest path. Here is the strongest case against me.

Brand advertising that makes no product claim at all is not automatically barred. You can advertise a company, a look, a set of values, an availability. Skilled agencies do build UK campaigns inside that space, and dismissing paid entirely leaves a channel on the table for brands with the budget and the discipline to stay purely brand-led.

Organic also has a specific UK weakness worth naming. The content that ranks in wellness categories is typically the content that answers a health question, and you are barred from answering health questions. That is a narrower content strategy than an American brand enjoys, and anyone selling you UK CBD SEO without acknowledging the constraint is overselling.

The honest position: both channels are constrained here, more than either is in America, and the right mix depends on your product’s status, your risk appetite, and whether you have counsel on retainer. Anyone offering a universal answer has not asked enough questions.

Frequently Asked Questions

Can I advertise CBD in the UK at all?

You can advertise the product’s existence, its composition, and non-medicinal attributes. You cannot make medicinal claims for an unlicensed product, and since no CBD health claims are authorised on the GB register, health claims are effectively unavailable. Words including cure, restore, prevent, avoid, fight, and heal are treated as medicinal.

What is the FSA Public List and does it mean my product is approved?

It lists CBD food products on sale in England and Wales linked to a credible application progressing through the novel foods process. It is not approval. The FSA has said inclusion means only that authorisation is being sought, and that it does not endorse the sale of any CBD food product. Claiming or implying FSA approval on the strength of a listing has been ruled a breach.

What happens if my product is not on the list?

The FSA has recommended to local authorities that products absent from the list, or marked as removed, be withdrawn from the market. Enforcement sits with those authorities.

Are my founder’s Instagram posts regulated?

Yes. The ASA has investigated posts from personal accounts of company directors and owners, and from brand ambassadors, treating them as advertising under the Code. Pre-approve that content the same way you would a paid ad.

Can an American agency work UK CBD brands?

For build, technical work, and organic infrastructure, yes. For anything touching claims, only with UK review in place. The risk profile differs categorically: the American downside is a civil penalty, while advertising an unauthorised medicinal product in Great Britain is a criminal offence under the Human Medicines Regulations 2012.

What is the daily intake figure I should be using?

The FSA’s provisional acceptable daily intake is 10mg per day for an average adult, revised down from a previous 70mg figure. The ASA has ruled advertising misleading for citing the older number. Audit your published content for it today.

Does any of this apply differently in Northern Ireland?

Yes. Consultation requests on novel food status for Northern Ireland businesses are assessed by the European Commission rather than the FSA, and CAP recommends marketers obtain legal advice for campaigns appearing in Northern Ireland given the complexities involved. Treat it as a separate jurisdiction rather than an afterthought.